(TheNewswire)
Thetford Mines, Quebec – TheNewswire - June 12, 2024 – KDA Group Inc. (TSXV: KDA) (“ KDA ” or the“ Corporation ”), a leader in healthcare andmedical technology innovation, is proud to announce the launch ofMedherize, its revolutionary new platform dedicated to the clinicalmanagement of patients requiring specialized medications. Thispioneering project particularly focuses on CDK 4/6 inhibitors used inthe treatment of breast cancer, with the objective of ensuring optimaland personalized patient follow-up.
Medherize marks the first collaboration amongspecialist doctors, pharmacists and patients to offer integrated andcoordinated care. KDA’s new clinical management solution is designedto address the complex challenges associated with the administrationof CDK 4/6 inhibitors, essential medications in the treatment ofcertain types of breast cancer. This innovative technology offers anintegrated platform enabling healthcare professionals to accuratelymonitor patient treatments, track side effects and adjust doses inreal-time while ensuring seamless communication between patients andcare providers.
Key Features of Medherize :
-
Personalized PatientFollow-Up : An intuitive user interface allowingdoctors to personalize and track treatment plans for each patient,ensuring better adherence to prescribed therapies.
-
Real-Time Monitoring : Integration of monitoring devices that collect real-timedata on patients’ health status, enabling rapid intervention whenneeded.
-
Side Effect Management : A proactive notification system to monitor and managepotential side effects of CDK 4/6 inhibitors.
-
Optimized Communication : A secure communication platform facilitating exchangesbetween patients, doctors and pharmacists, thereby enhancing carecoordination.
-
Analysis and Reporting : Advanced analytical tools to generate detailed reports ontreatment effectiveness, supporting evidence-based clinicaldecision-making.
“We are thrilled to launch Medherize, a newtechnology that represents a significant step toward better healthcaremanagement for breast cancer patients. Our solution is designed tosupport healthcare professionals in their mission to provide optimizedand personalized treatments, while improving patients’ quality oflife,” said Marc Lemieux, Chief Executive Officer of KDA.
This pilot project, the first of its kind, will be deployedin the Corporation’s partner clinics and hospitals in the comingmonths, with ambitions to expand internationally. KDA remainscommitted to investing in innovation and closely collaborating with healthcare professionals to continue developing cutting-
edge solutions that meetthe evolving needs of the healthcare sector. Artificial intelligenceand new technologies could reduce healthcare spending by $200 to $360billion. 1
ABOUT KDA GROUP
KDA Group is a leader in technological innovations andspecialized software solutions (SAAS – Software as a Service) forthe healthcare professionals’ market. KDA is a corporation thatoffers quality products and has a respected expertise among thevarious stakeholders in the pharmaceutical and medical sectors. Thetechnology products developed by KDA aim, among other things, toaccelerate the healthcare’s digital transformation, and areavailable for the Canadian and international markets. Additionalinformation about the Corporation is available at www.kdagroup.com and onSEDAR+ at www.sedarplus.ca .
- 30 -
REFERENCE
1- David M. Cutler et al., Thepotential impact of artificial intelligence on healthcare spending,National Bureau of Economic Research working paper, number 30857,January 2023.
CAUTION REGARDINGFORWARD-LOOKING STATEMENTS
This press release from KDA Groupcontains forward-looking statements. Forward-looking statements aretypically identified by the words assumption , goal , guidance , objective , outlook , strategy , target, and other similar expressions, or futureor conditional verbs such as aim , anticipate , believe , predict , could , expect , intend , may , plan , seek , should , strive, and will . By their nature, forward-looking statements require us to makeestimates and assumptions and express opinions based on currentconditions and anticipated developments, as well as other factors thatManagement may deem appropriate under the circumstances. There isinherent uncertainty and significant risk in these estimates,assumptions, and opinions, particularly of a commercial, economic, andcompetitive nature, and they are therefore subject to change. KDAGroup cannot guarantee that these estimates, assumptions, and opinionswill prove to be accurate.
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this press release.
INFORMATION
Marc Lemieux, Chief Executive Officer
514 622-7370
Copyright (c) 2024 TheNewswire - All rights reserved.